Surgical resection of primary tumor improves survival of pancreatic neuroendocrine tumor with liver metastases

Lianyuan Tao; Dianrong Xiu; Abuduhaibaier Sadula; Chen Ye; Qing Chen; Hanyan Wang; Zhipeng Zhang; Lingfu Zhang; Ming Tao; Chunhui Yuan

doi:10.18632/oncotarget.19523

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Clinical Research Papers:

Surgical resection of primary tumor improves survival of pancreatic neuroendocrine tumor with liver metastases

Lianyuan Tao, Dianrong Xiu, Abuduhaibaier Sadula, Chen Ye, Qing Chen, Hanyan Wang, Zhipeng Zhang, Lingfu Zhang, Ming Tao and Chunhui Yuan _

PDF | HTML | How to cite

Oncotarget. 2017; 8:79785-79792. https://doi.org/10.18632/oncotarget.19523

Metrics: PDF 1465 views | HTML 3074 views | ?

Abstract

Lianyuan Tao1,*, Dianrong Xiu1,*, Abuduhaibaier Sadula1, Chen Ye1, Qing Chen1, Hanyan Wang1, Zhipeng Zhang1, Lingfu Zhang1, Ming Tao1 and Chunhui Yuan1

1Department of General Surgery, Peking University Third Hospital, Beijing 100191, China

*These authors contributed equally to this work

Correspondence to:

Chunhui Yuan, email: [email protected]

Keywords: pancreatic neuroendocrine tumor, liver metastasis, prognosis, surgical resection, survival

Received: May 25, 2017 Accepted: July 13, 2017 Published: July 24, 2017

ABSTRACT

This study investigates survival of patients diagnosed with pancreatic neuroendocrine tumor with liver metastases based on local treatment on the primary tumor. Patients diagnosed with stage IV PNET between 2010 and 2014 were identified from the Surveillance Epidemiology and End Results database. Cancer-Specific Survival and Overall Survival were examined. A total of 191 patients with pancreatic neuroendocrine tumor with liver metastases were included in this analysis. There were 47 patients (24.6%) who received surgical resection and 144 (75.4%) who did not. Patients with N1 stage was more likely to be treated with surgical resection. The results showed that surgical resection of primary tumor was associated with Cancer-Specific Survival (p = 0.028) and Overall Survival (p = 0.025) benefit. Not receiving surgery, being unmarried and N1 stage are factors associated with poor survival. This study reveals that local treatment on the primary benefits both Cancer-Specific Survival and Overall Survival in PNET patients with LM. This may be suggestive for the management on this patient population.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 19523

Publication Alerts

Clinical Research Papers:

Surgical resection of primary tumor improves survival of pancreatic neuroendocrine tumor with liver metastases

Abstract